What is the fair value of Innate Pharma SA (OTC-IPHY.F) stock?

The current fair value estimate for Innate Pharma SA (OTC-IPHY.F) is $1.96. This implies an estimated upside of 18.8% versus the current market price.

Is Innate Pharma SA (OTC-IPHY.F) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 18.8% versus the current market price.

How is the financial health of Innate Pharma SA?

The current financial health read for Innate Pharma SA (OTC-IPHY.F) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Innate Pharma SA's next earnings date?

The next earnings date currently listed for Innate Pharma SA (OTC-IPHY.F) is November 5, 2026.

Does Innate Pharma SA (OTC-IPHY.F) pay dividends?

The latest available data indicates no current dividend yield for Innate Pharma SA (OTC-IPHY.F).

What is the market capitalization of Innate Pharma SA?

The current market capitalization listed for Innate Pharma SA is 165 M.

What is the enterprise value of Innate Pharma SA?

The current enterprise value listed for Innate Pharma SA is 163.2 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Innate Pharma SA?

The ticker symbol for Innate Pharma SA is OTC-IPHY.F, and the stock is listed on OTC Markets.

Where is Innate Pharma SA (OTC-IPHY.F) listed?

Innate Pharma SA (OTC-IPHY.F) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Innate Pharma SA?

The current debt-to-total-capital ratio listed for Innate Pharma SA is 12.4%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Innate Pharma SA?

The free float listed for Innate Pharma SA is 75.2%. Free float helps investors understand how much of the share base is available for public trading.

Innate Pharma SA (IPHYF) Fair Value & Stock Analysis

Innate Pharma SA (IPHYF)

Innate Pharma S.A. is a France-based biotechnology company focused on developing immunotherapies for cancer patients in France and other international markets. The company’s pipeline includes several clinical-stage candidates, such as Lacutamab (IPH4102) for cutaneous T-cell and peripheral T-cell lymphoma and refractory Sézary syndrome, Monalizumab for advanced solid tumors including colorectal, lung, and head and neck cancers, and IPH5201, which targets the CD39 immunosuppressive pathway. Additional programs include IPH5301, IPH6401, IPH6101, and IPH62, along with preclinical assets such as IPH43, IPH45, and IPH67. Innate Pharma also maintains licensing, collaboration, and co-development arrangements with AstraZeneca, Novo Nordisk A/S, Sanofi, Orega Biotech, and MedImmune Limited. The company was incorporated in 1999 and is based in Marseille, France. Its common stock is listed on OTC Markets.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
OTC-IPHY.F	$1.96	18.8% Upside	Undervalued	Not available	Not available	Weak	0.0%	November 5, 2026	14.7x	165 M	163.2 M	12.4%	75.2%	-51.8	90.2%